A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Administration of HM12470 in Subjects With Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Hanmi Pharmaceutical Company
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for T1DM:
- T2DM more than 12 monthM
- Age ≥18 and ≤70 years
- Body mass index between 18.0 and 35.0 kg/m2 inclusive.
- Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
- Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for >12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug.
- Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
Inclusion Criteria for T2DM:
- T1DM more than 12 monthM
- Age ≥18 and ≤70 years
- Body mass index between 18.0 and 30.0 kg/m2 inclusive.
- Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
- Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for >12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug.
- Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
Exclusion Criteria
- A subject who has proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator
- Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis
- pregnant or lactating women
- participation in an investigational study within 30 days prior to dosing
- Clinically significant abnormal ECG at screening, as judged by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1
Very low dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
|
|
Experimental: Cohort 2
Low dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
|
|
Experimental: Cohort 3
Intermediate dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
|
|
Experimental: Cohort 4
High dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
|
|
Experimental: Cohort 5
Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
Single dose subcutaneous administration of active comparator
|
|
Experimental: Cohort 6
Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
|
Single dose subcutaneous administration ranging from a very low dose to high dose
Single dose subcutaneous administration of active comparator
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence and severity of treatment emergent adverse events
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Plasma Concentration(Cmax) of HM12470 following a single dose
Time Frame: 1 month
|
Pharmacokinetic properties of HM12470 following a single dose will be assessed in plasma using a validated assay
|
1 month
|
|
Area under the concentration-time curve (AUC) of HM12470 following a single dose
Time Frame: 1 month
|
Pharmacokinetic properties of HM12470 following a single dose will be assessed in plasma using a validated assay
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Hanmi Pharmaceuticals Hanmi Pharmaceuticals, Hanmi Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HM-INS115-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.